In the space of a day, two AI stories broke into the mainstream. They were, in different ways and from different insider perspectives, about the same thing: becoming suddenly, and profoundly, worried ...
A marriage of formal methods and LLMs seeks to harness the strengths of both.
I'm sorry NixOS, I've failed you.
RXRX has reported updated data from its ELUCIDATE and TUPELO trials, but the stock has failed to mount a sustained rally. The ELUCIDATE update provides just an additional 10 patients of data treated ...